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Abstract
Background: Treatment failure for esophageal carcinoma is frequently due to lymph node metastasis and invasion
to neighboring organs. The aim of the present study was to investigate invasion- and metastasis-related genes in
esophageal carcinoma cells in vitro and in vivo.
Methods: A metastasis model using a Matrigel invasion clonal selection approach was employed to establish a
highly invasive subline EC9706-P4 from the esophageal carcinoma cell (ESCC) line EC9706. The differentially
expressed genes of the subline and the parental cells determined by gene microarrays were further analyzed by
RT-PCR and Western blotting.
Results: We identified sphingosine kinase 1 (SPHK1) as an invasion and metastasis-related gene of esophageal
cancer. SPHK1 was overexpressed in the EC9706-P4 subline with high invasive capacity. Among six ESCC lines
tested, KYSE2 and KYSE30 cells showed the highest SPHK1 mRNA and protein expressions as well as the most
invasive phenotype. By Western blotting, in 7/12 cases (58%), SPHK1 expression was higher in esophageal
carcinomas than in the companion normal tissue. In 23/30 cases (76%), SPHK1 protein expression was upregulated
in the tumors compared to matched normal tissue by immunohistochemistry (IHC). Esophageal carcinoma tissue
microarray analysis indicated that SPHK1 expression correlated with the depth of tumor invasion (P < 0.0001) and
lymph node metastasis (P = 0.016). By Kaplan-Meier analysis, strong SPHK1 expression was significantly associated
with clinical failure (P < 0.01), suggesting the involvement of SPHK1 in aggressiveness of human esophageal
carcinoma. SPHK1 overexpression significantly increased the invasiveness of EC9706 cells in vitro and also increased
EC9706 cell growth and spontaneous metastasis in vivo, promoting significant increases in tumor growth, tumor
burden and spontaneous lung metastasis in nude mice. SPHK1 expression significantly correlated with the
expression of many EGFR pathway genes associated with invasion of cancer cells. SPHK1 protein expression also
significantly correlated with the phosphorylation of EGFR.
Conclusion: In summary, our data implicate SPHK1 in the metastasis of esophageal cancer. Our study also
identified downstream mediators of SPHK1 in esophageal cancer cells that may mediate enhanced malignant
behavior, and several of these mediators may be useful as therapeutic targets.
Introduction
Human esophageal carcinoma, one of the most common
causes of cancer death worldwide, occurs at a very high
frequency in China [1,2]. Esophageal carcinomas often
have poor prognosis due to early lymph node metastasis
and invasion of neighboring organs such as the aorta, tra-
chea, bronchus, pericardium and lung [2]. Therefore,
disrupting the aggressive metastatic phenotype is essen-
tial for developing an effective treatment for esophageal
cancer. Although several molecules have been reported
to contribute to the ability of esophageal carcinoma cells
to metastasize and invade normal tissue, such as N-cad-
herin [3], TSLC1 [4] and MTA1 [5], the underlying
mechanism remains obscure. Considering the complexity
of tumor invasion and metastasis, various experimental
approaches have been developed to systematically iden-
tify genes that are involved in the process. By directly
comparing the differentially expressed genes between
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encoding the periostin protein, was identified as a gene
associated with colon cancera n dl i v e rm e t a s t a s i s[ 6 ] .
Cancer metastasis is thought to originate from a small
proportion of cancerous cells in primary tumors. There-
fore, screening for a subpopulation of cells with high
metastatic potential from a parent tumor cell line in
experimental models is a well-defined method for disco-
vering genes that play roles in metastasis, especially that
which preferentially occurs in specific organs. For exam-
ple, microarray analysis of sublines of the MDA-MB-231
cell line with high lung or bone metastatic selection in
nude mice led to identification of a set of genes that
mark or mediates breast cancer metastasis in these tis-
sues [7-9].
In order to derive a subpopulation of cells with high
metastatic potential from tumor cell lines, we have
established a model system to inspect genes involved in
different steps of metastasis including invasion, survival
and arrest. We screened for and selected an esophageal
tumor cell subline with high invasive potential and ana-
lyzed genes which may correspond to this phenotype by
gene microarray. Through this analysis, we identified
sphingosine kinase 1 (SPHK1) as one such gene that par-
ticipates in esophageal carcinoma invasion and
metastasis.
SPHK1 is a conserved lipid kinase that catalyzes forma-
tion of important regulators of inter- and intracellular sig-
naling. It is a ubiquitously expressed, evolutionary
conserved enzyme that catalyzes phosphorylation of sphin-
gosine (Sph) and dihydrosphingosine (dhSph) to sphingo-
sine 1-phosphate (S1P) and dhS1P, respectively. SPHK1 is
transiently activated in response to a large variety of ago-
n i s t sa n dh a sb e e ns h o w nt oc o n tribute to signaling cas-
cades elicited by TNF-a [10], VEGF and 17b-estradiol [11].
Accordingly, SPHK1 can mediate biological effects of TNF-
a such as induction of COX2 and generation of PGE2 in
fibroblastic cells and MCP-1 in endothelial cells [12].
Of interest is that SPHK1 mRNA is frequently overex-
pressed in a variety of solid tumors, suggesting an impor-
tant role for its encoded enzyme during tumorigenesis.
Overexpression of SPHK1 is thought to be oncogenic and
renders transfected cells chemoresistant. Bonhoure et al.
[13] reported that targeting SPHK1 overcomes the multi-
drug- resistant gene (MDR)-associated chemoresistance
of HL60 cells. The oncogenic properties of SPHK1 have
been demonstrated both in vitro and in vivo in experi-
mental models based on its overexpression in NIH3T3
cells [14]. Overexpression of SPHK1 facilitates ancho-
rage-independent growth in vitro and leads to tumor for-
mation in SCID mice. Furthermore, more recent studies
have demonstrated that phosphorylation of SPHK1 and
subsequent membrane translocation are required for its
pro-oncogenic function. Overexpression of SPHK1
up-regulates MMP1 mRNA and promoter activity as well
as its protein levels, and this action by SPHK1 requires
activation of the ERK1/2-Ets1 and NF-kB pathways [12].
In addition, high levels of the SPHK1 enzyme and its
downstream product, S1P, correlate with poor survival of
glioblastoma patients [15,16], and this unusual enhance-
ment of neural cell invasion requires upregulation of the
matricellular protein CCN1/Cyr61. These data suggest
that enhanced SPHK1 activity in glioblastoma may drive
the invasive potential of these cells.
Few studies by other investigators have specifically ana-
lyzed the effect of SPHK1 on invasiveness of cancer cells.
Our report is the first to implicate the involvement of
SPHK1 in the metastasis of esophageal cancer. We
observed the overexpression of SPHK1 transcripts in eso-
phageal carcinoma and identified downstream mediators
that may mediate enhanced malignant behavior in these
tumor cells. As several of these mediators may be useful
as therapeutic targets of esophageal carcinoma, our find-
ings will have implications for cancer drug development.
Materials and methods
Cell culture conditions
The esophageal carcinoma cell (ESCC) line EC9706 (a
gift from Dr. Minrong Wang, Chinese Academy of Medi-
cal Sciences Cancer Institute Hospital, Peking University
Medical School, Beijing, China) was cultured in RPMI
1640 supplemented with 10% fetal bovine serum (FBS).
Other ESCC lines (KYSE30, KYSE150, NEC, KYSE510,
and KYSE2) were generously provided by Dr.Y. Shimada,
Kyoto University.
Selection of invasive sublines from EC9706 cells
To select a highly invasive subpopulation, EC9706 cells
were seeded on a Matrigel (Becton Dickinson, Franklin
Lakes, NJ) coated, 8 μm-pore transwell (Costar, Cam-
bridge, MA). 24 hours later, cells that had invaded to the
other side of the transwell membrane were collected,
expanded and then re-seeded into another Matrigel coated
transwell. Such selection rounds for highly invasive cells
were repeated four times, resulting in a subline from each
generation designated as EC9706-P1, EC9706-P2, EC9706-
P3 and EC9706-P4.
Quantitative RT-PCR
QRT-PCR was performed as my previous manuscript
described [17-20], briefly cells were harvested in Trizol
®
reagent (Invitrogen, Carlsbad, CA), and total RNA was iso-
lated according to the manufacturer’s instructions. Single-
stranded cDNA was synthesized from 4 μgt o t a lR N A
using M-MLV reverse transcriptase (Invitrogen), with an
oligo(dT) 18-mer as the primer, in a final reaction volume
of 25 μl. Amplifications of specific transcripts from the
cDNA were performed using the following primers:
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Page 2 of 15SPHK1 sense 5’-ACAGTGGGCACCTTCTTTC-3’,a n t i -
sense 5’-CTTCTGCACCAGTGTAGAGGC -3’; SPHK2
sense 5’-GCACGGCGAGTTTGGTTC-3’,a n t i s e n s e5’-
GAGACCTCATCCAGAGAGACTAG-3’;T M 4 S F 3sense
5’-CCAAACCCAGTATCTCA-3’,a n t i s e n s e5 ’-G A C A A
GCCTGTAACGAA-3’; Integrin a6 sense 5’-G C CT T G
CAC GAT GAT ATG GAG-3’,a n t i s e n s e5 ’-G A TG A G
CTG TCT GGAGAA-3’; Integrin b4 sense 5’-G C A T C G
TGGTCATGG AGAGCAG-3’, antisense 5’- AATGTCCC
TCGTGCACACAGC-3’; MET sense 5’-C A T G C C G A -
CAAGTGCAGTA-3’, antisense 5’- TCTTGCCATCATT
GTCCAAC-3’; GAPDH sense 5’- TGGTATCGTGGAAG-
GACTCATGAC-3’,a n t i s e n s e5 ’- ATGCCAGTGAGCTTC
CCGTTCAGC-3’; ADAM12m sense 5’- GCACCTCCCT
TCTGTGACAAGTTT-3’, antisense 5’- CTTGGTGTGGA
TATTGTGGAGCAG-3’; CLDN1 sense 5’- GCGCGA-
TATTTCTTCTTGCAGG-3’,a n t i s e n s e5 ’- TTCGTACC
TGGCATTGACTGG-3’; IGFBP1 sense 5’- ATCT-
GATGGCCCCTTCTGAA-3’,a n t i s e n s e5 ’- AGCCTTC-
GAGCCATCATAGGTA-3’; A2M sense 5’- ACCAGGAC
GATGAAGACTGCAT-3’, antisense 5’- CCACGAATCA-
CAGAGTAAGGCA-3’; Integrin a3 sense 5’-A A G C -
CAAGTCTGAGACT-3’,a n t i s e n s e5 ’- GTAGTATTGG
TCCCGAGTCT-3’; TFPI2 sense 5’- CGCCGGATCC
TTTCTCGGAC-3’, antisense 5’- GAATGTCTCGAGTTG
CTTCTTCCGA-3’; LOXL2 sense 5’- GGCCGCCAC
GCGTG GATC-3’,a n t i s e n s e5 ’- CCCAAGGGTCAGG-
TAGCAGCCCC-3’; CYR61 sense 5’- AGCCCAACTG-
TAAACATCAG-3’,a n t i s e n s e5 ’- CATCCAGCGTA
AGTAAACCT-3’; TIMP3 sense 5’- TTCGGTTACCC
TGGCTACCA-3’,a n t i s e n s e5 ’-C T G C A GT A G C C G
CCTTCT-3’.
Tissue samples and IHC
Samples were obtained from patients who attended Chi-
nese Academy of Medical Sciences Cancer Hospital from
January 2001 to December 2005. Ethical approval was
provided by the Chinese Academy of Medical Sciences
Cancer Hospital Ethics Committee. None of the patients
received any neoadjuvant therapy prior to surgery. Prior
patient consent and approval from the Institute Research
E t h i c sC o m m i t t e ew e r eo b t a i n e db e f o r ew eu s e dt h e s e
clinical materials for research purposes. Paired samples
of fresh normal esophageal tissues and esophageal carci-
noma tissues from the same patient were collected by the
Department of Pathology in the Chinese Academy of
Medical Sciences Cancer Hospital (Beijing, China). Each
patient had received a pathologically and clinically con-
firmed diagnosis of esophageal squamous cell carcinoma.
Primary tumor regions and the corresponding histologi-
cally normal esophageal mucosa were separated by
experienced pathologists and immediately stored at -70°C
until use. None of the patients received treatment before
surgery.
The expression of SPHK1 in the esophageal tumors was
determined by assessing its staining using tissue microar-
rays from 154 clinical cases, of which 124 of the esopha-
geal cancer specimens had clinical follow-up records,
these patients were followed up 8 years and 117 patients
died at the end-points. In addition, 30 of these specimens
had paired normal epithelia. For immunostaining of
SPHK1, a DAKO CSA kit was used. The anti-SPHK1 anti-
body (ab16491, Abcam, 10 μg/ml) was incubated with the
sectioned tissues for 1 h in citrate buffer. After staining,
the slides were evaluated by two pathologists. SPHK1
expression was determined by scoring intensity and per-
centage of staining. Tissues with no staining were rated as
0; those with faint staining or moderate to strong staining
in < 25% of cells as 1; with moderate staining or strong
staining in 25-50% of cells as 2; and with strong staining in
> 50% of cells as 3.
Immunofluorecence
Cells were fixed in 4% paraformaldehyde and then per-
meablized with 0.2% Triton X-100. Coverslips were
blocked with 10% non-immune sheep serum. Primary
antibodies were diluted in 1% bovine serum albumin/PBS
and incubated overnight at 4°C. The antibody against
SPHK1 (ABIN552700, poly rabbit antibody, 1:50) was
obtained from http://antibodies-online.com. The second-
ary antibody was Cy5-conjugated goat anti-rabbit IgG
(Jackson Immunoresearch Laboratories Inc., West Grove,
PA). Coverslips were mounted on glass sides with 0.5 μg/
ml DAPI/fluorescence protection agent. Images were
acquired with an Olympus confocal microscope.
Generation of SPHK1 overexpressing cells
The human SPHK1 cDNA was cloned into the
pcDNA4.0 expression vector (Invitrogen) containing a
c-myc epitope at the C-terminus to give the pcDNA4.0-
SPHK1-c-myc vector. The SPHK1 expression vector was
transfected into EC9706 cells using Lipofectamine 2000
(Invitrogen), according to the manufacturer’s recom-
mendations. Cells carrying the recombinant SPHK1 or
empty (control) vector were selected by culturing in the
presence of 200 ng/ml Zeocin (Invitrogen) for more
than 4 weeks. Two SPHK1 stably transfected EC9706
cell clones (C17, C24) and one SPHK1 negative clone
(C7) were chosen for subsequent experiments. Transfec-
tion of duplex siRNAs was performed in the same man-
ner. The SPHK1 siRNA sequences as used before [21]
were 5’-GGGCAAGGCCUUGCAGCUCd(TT)-3’ and 5’-
GAGCUGCAAGGCCUUGCCCd(TT)-3’, control siRNA
5’-UUCUCCGAACGUGUCACGUd(TT)-3’.
Invasion assays
Invasion assays were carried out similarly to the proce-
dure for selecting invasive cell lines described above [17].
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Page 3 of 15Briefly, 1 × 10
4 cells were placed in a 24-well transwell
unit on polycarbonate filter with 8 μm pores coated with
Matrigel. After a 24-h incubation period, the cells that
h a dp a s s e dt h r o u g ht h ef i l t e r into the lower wells were
stained, counted and photographed. All experiments
were performed in triplicate and repeated twice.
Western blot analysis
The proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and then transferred to
polyvinylidene difluoride membranes (Millipore, Bedford,
MA). Blots were blocked and then probed with antibodies
against the tag of SPHK1 protein c-myc (9E10 1:3000,
Sigma, St. Louis, MO) or directlly against the SPHK1 pro-
tein (1 μg/ml, ab16491, Abcam), b-actin (1:5000, Sigma,
St. Louis, MO), phospho-EGFR (Y1068,1:1000, Invitrogen),
EGFR(1:1000, Invitrogen). After washing, the blots were
incubated with horseradish peroxidase-conjugated second-
ary antibodies and visualized using an enhanced chemilu-
minescence kit (Pierce, Rockford, IL).
Xenograft assays in nude mice
Female nu/nu mice, obtained from the Jackson Laboratory
(Vitalriver, China), were kept in a specific pathogen-free
facility at the Experimental Center of the Chinese Acad-
emy of Medical Sciences, Beijing, China. We are ensure
animals used for scientific purposes are treated and cared
for ethically and humanely. Female mice, aged 4-6 weeks,
were used in these experiments. Parental EC9706, SPHK1
transfected EC9706 clones C17 and C24, or vector trans-
fected cells were each subcutaneously injected into eight
nude mice. Three months after the injection, the mice
were sacrificed and examined for subcutaneous tumor
growth and metastasis development. The tumor volumes
were calculated according to the following formula:
volume = length × width
2/2. After the last treatment, the
mice were sacrificed, and the tumor volumes and weights
were measured. Xenografts were detected using the anti-
SPHK1 antibody (10 μg/ml, ab16491, Abcam) with each
section examined.
Statistical analysis
All data are presented as mean ± standard deviation
(SD). Statistical analysis was performed using the Statis-
tical Package for the Social Sciences (SPSS) (SPSS Inc.,
Chicago, IL). Student’s two-tailed t-test was used to
compare the groups. P ≤ 0.05 was considered significant.
Results
SPHK1 is overexpressed in the EC9706-P4 subline with
high invasive capacity
To establish an esophageal carcinoma invasion model,
EC9706 cells were seeded onto Matrigel-coated trans-
wells. The cells were allowed to invade into the lower
chamber of the transwell, collected, expanded and then
re-seeded onto another Matrigel-coated transwell. Cells
were harvested after four rounds of selection, resulting
in the establishment of a relatively stable, highly invasive
subline, EC9706-P4. The invasive ability of this line was
about 15-fold greater than that of the parent cell line,
EC9706, in matrigel invasion tests, but equal to that of
the third selection round line, EC9706-P3 (Figure 1A),
suggesting that the metastatic potential of the sublines
reached a plateau by the fourth round of selection.
Thus, by Matrigel invasive subpopulation selection, we
were able to establish the highly invasive and metastatic
esophageal carcinoma cell line EC9706-P4.
The gene expression profiles of EC9706 and EC9706-
P4 were then analyzed by microarrays. Between these cell
lines, 124 genes were differentially expressed, including
71 upregulated genes and 53 downregulated genes in
EC9706-P4 relative to EC9706 (cutoff, fold ≥ 2.0, Addi-
tional file 1). Most of the dysregulated genes have been
previously shown to be involved in tumor invasion and
metastasis, such as TFPI-2 [17], LOXL2 [22-24],
ADAM12m [25,26], IGFBP1 [27,28], integrin a6[29,30],
CD44 [31]and CYR61 [32]. Expression of some of these
genes were subsequently tested by QRT-PCR (Figure 1B).
One of these genes, SPHK1, was of particular interest to
our study. Trojanowska et al. showed that overexpression
of SPHK1 up-regulated MMP1 mRNA and promoter
activity as well as its protein levels [12], and the MMP1
gene is known to play a very important role in the inva-
sion of esophageal cancer. We found by QRT-PCR analy-
sis that SPHK1 expression gradually increased with each
round of selection from the EC9706 parent cells to the
highly invasive EC9706-P4 subline (Figure 1B).
SPHK1 is upregulated in esophageal carcinoma and
correlates with invasion and clinical outcome
SPHK1 expression was analyzed by RT-PCR and immuno-
fluorecence in esophageal carcinoma cell lines, including
KYSE30, KYSE150, KYSE510, KYSE2, EC9706, and NEC
cells (Figure 2A). In these cell lines, SPHK1 was detected
by PCR after 35 cycles (Figure 2B). KYSE2 and KYSE30
cells showed the highest SPHK1 expression at both the
mRNA and protein levels, and they were also the most
invasive lines among the six cell lines tested (Figure 2C).
To assess SPHK1 protein expression in esophageal carci-
noma tissues, 12 paired samples, each consisting of eso-
phageal carcinoma tissue and normal esophageal tissue
from the same patient, were analyzed by Western blotting.
SPHK1 protein was found to be overexpressed in seven of
t h et w e l v e( 5 8 % )e s o p h a g e a lcarcinoma tissues; that is,
SPHK1 expression was higher in the tumor tissue than in
the companion normal tissue (Figure 3A). We then
extended this analysis by performing immunohistochemis-
try (IHC) on 30 pairs of esophageal-carcinoma and normal
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Page 4 of 15Figure 1 Overexpression of SPHK1 in the esophageal carcinoma EC9706-P4 subline with high invasive capacity. EC9706 cells were
seeded onto Matrigel-coated transwells and allowed to invade into the lower chamber of the transwell, collected, expanded and then re-seeded
onto another Matrigel-coated transwell. After four rounds of selection, the relatively stable, highly invasive subline, EC9706-P4, was established.
(A) Transwell invasion analysis showed the invasive ability of EC9706-P4 was about 15-fold greater than the parent cell line EC9706 (P < 0.05) (B)
The differential gene expression profiles of EC9706 and EC9706-P4 were analyzed by microarray, and expression of some genes were confirmed
by QRT-PCR. Most of the dysregulated genes were previously associated with tumor invasion and metastasis. Notably, SPHK1 expression gradually
increased through each round of selection from EC9706 to EC9706-P4.
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Page 5 of 15Figure 2 Correlation of SPHK1 expression with invasiveness of esophageal carcinoma cell lines. (A, B) SPHK1 expression was analyzed by
RT-PCR and immunofluorecence in the esophageal carcinoma cell lines: KYSE30, KYSE150, KYSE510, KYSE2, EC9706 and NEC. (B) In these cell
lines, SPHK1 was detected by PCR after 35 cycles. (C) Invasion assays were carried out by seeding 1 × 10
4 cells in a 24-well transwell unit on
polycarbonate filter with 8-μm pores coated with Matrigel. After a 24-h incubation period, the cells that had passed through the filter into the
lower wells were stained, counted and photographed. All experiments were performed in triplicate and repeated twice. KYSE2 and KYSE30 cells
showed the highest SPHK1 expression at the mRNA and protein levels, and they were also the most invasive among the six cell lines.
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Page 6 of 15Figure 3 Upregulation of SPHK1 in esophageal carcinoma and correlation with clinical outcome. SPHK1 protein expression was assessed
in esophageal carcinoma tissues. (A) Twelve sample pairs, each consisting of esophageal carcinoma tissue and normal esophageal tissue from
the same patient, were analyzed by Western blotting. SPHK1 was overexpressed in seven of twelve esophageal carcinoma tissues (58%)
compared to the companion normal tissue. (B) The expression SPHK1 in 30 pairs of esophageal-carcinoma and normal tissues were also
analyzed by IHC. In 23 of 30 cases (76%), SPHK1 expression appeared to be upregulated in the tumors when compared to the companion
normal tissue with the following immunostaining scores: normal: 0.93 ± 0.173; tumor: 2.06 ± 0.46, P < 0.01. (C-D) SPHK1 protein expression in an
esophageal carcinoma tissue microarray (n = 274 tissue microarray elements from 124 cases of esophageal squamous carcinoma). By Kaplan-
Meier analysis, strong SPHK1 expression (staining intensity equal to, or greater than, 2) was significantly associated with clinical failure, whereas
the weak SPHK1staining (staining intensity less than 2) was found in individuals with delayed clinical failure, P < 0.01.
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Page 7 of 15tissues. In 23 cases (76%), SPHK1 expression appeared to
be upregulated in the tumors when compared to the com-
panion normal tissue with the following immunostaining
scores: normal: 0.93 ± 0.173; tumor: 2.06 ± 0.46, P < 0.01
(Figure 3B). We then evaluated the expression of SPHK1
protein in an esophageal carcinoma tissue microarray (n =
274 tissue microarray elements from 124 cases of esopha-
geal squamous carcinoma) (Figure 3C). The expression
rates of SPHK1 in cases from tussue microarrays is that
18/124 (14.5%) cases with no SPHK1 expression, 17/124
(13.7%) cases with SPHK1 expression score 1, 32/124
(25.8%) cases with SPHK1 expression score 2 and 57/124
(46.0%) cases with SPHK1 score 3. Statistical analysis indi-
cated that in the esophageal carcinoma, the SPHK1 expres-
sion correlated with the depth of tumor invasion (P <
0.0001) and lymph node metastasis (P = 0.016) (Table 1).
There was no significant association with age, sex and
tumor differentiation.
We therefore examined whether expression of the
SPHK1 protein could be used to predict clinical out-
come in esophageal carcinoma patients with available
survival information. By Kaplan-Meier analysis, strong
SPHK1 expression (staining intensity ≥ 2) was
significantly associated with clinical failure, whereas the
weak SPHK1 staining (staining intensity less than 2) was
found in individuals with delayed clinical failure (P <
0.01) (Figure 3D). These findings further suggest that
SPHK1 overexpression is significantly associated with
aggressive human esophageal carcinoma.
SPHK1 upregulates esophageal carcinoma invasive and
spontaneous metastasis potential
We next assessed the impact of transfection-mediated
SPHK1 gene upregulation in EC9706 cells. Several SPHK1
stable transfected clones were screened and two of them,
SPHK1-C17 and SPHK1-C24, had markedly upregulated
expression of SPHK1 in EC970 cells (Figure 4A). In the
transwell invasion assay, upregulation of SPHK1 signifi-
cantly increased the invasiveness of EC9706 cells (Figure
4B). In the 3D Matrigel culture assays, SPHK1 overexpres-
sion significantly increased the diameter and the invasive
morphology (Figure 4C) as well as the proliferation (Figure
4D, F) of the EC9706 cell clones, but did not influence
their apoptosis levels in an Annexin V assay (Figure 4E, F).
We also examined whether SPHK1 could increase EC9706
cell growth and spontaneous metastasis in nude mice. The
SPHK1-C17 and SPHK1-C24 stable overexpressing clones
were tested in animal experiments and showed that the
SPHK1 gene promoted tumor growth and tumor burden
in nude mice. SPHK1 significantly promoted growth of
EC9706 xenografts (SPHK1-C17: 2.62 ± 1.12 cm
3;S P H K 1 -
C24: 2.78 ± 1.14 cm
3) compared to transfected control
(EC9706: 1.42 ± 0.854 cm
3) or control EC9706 cells
(EC9706-Ve: 1.35 ± 0.432 cm
3,A N O V AP <0 . 0 1F i g u r e
5B, D). Expression of SPHK1 increased weight of tumors
(SPHK1-C17: 2.42 ± 0.654 g; SPHK1-C24: 1.82 ± 0.542 g)
compared to transfected control (EC9706: 1.12 ± 0.454 g)
or control EC9706 cells (EC9706-Ve: 1.03 ± 0.434 g,
ANOVA P <0 . 0 1F i g u r e5 C ,D ) .W ea l s oo b s e r v e dt h a t
SPHK1 upregulation dramatically increased spontaneous
lung metastasis of EC9706 cells (SPHK1-C17:7.42 ± 3.43
cm
3; SPHK1-C24: 4.21 ± 1.34 cm
3)c o m p a r e dt ot r a n s -
fected control (EC9706: 1.34 ± 0.65 cm
3)o rc o n t r o l
EC9706 cells (EC9706-Ve: 0.63 ± 0.064 cm
3, ANOVA P <
0.05 Figure 5A, D). These studies support the view that
SPHK1 expression is vital for the maintenance of invasive
and metastatic potential of esophageal carcinoma cells.
SPHK1 promotes metastasis via activation of the EGFR
pathway
To glean mechanistic insight into the role of SPHK1 in
invasion and metastasis, we surveyed potential links
between this enzyme and key molecules of known rele-
vance to invasion. Western blot analysis indicated that
the expression of SPHK1 significantly correlated with the
phosphorylation of EGFR, while knockdown of SPHK1
by RNAi decreased EGFR phosphorylation in EC9706-P4
Table 1 SPHK1 correlated with depth of tumor invasion
and lymph node metastasis in esophageal carcinoma
Variables Score of SPHK1 expression P value
0123
Age, year 0.374
Mean 61.7 61.2 63.2 60.1
SD 11.0 12.8 11.9 14.3
Gender 0.494
Male 7 11 15 26
Female 11 6 17 31
pT (primary tumor) < 0.0001*
p T 0 0540
p T 1 1266
pT2 6 4 10 11
pT3 11 6 12 40
pN(lymphnode metastasis) 0.016*
pN0 14 10 16 17
pN1 4 7 16 40
Differentiation 0. 737
high 4 15 9 19
moderate 6 2 12 21
low 8 0 11 17
Expression of SPHK1 protein was analyzed in 124 cases of esophageal
squamous carcinoma. After staining, slides were evaluated by two
pathologists. SPHK1 expression was determined by scoring intensity and
percentage of cell staining. Tissues with no staining were rated as 0; those
with faint staining or moderate to strong staining in < 25% of cells as 1; with
moderate staining or strong staining in 25-50% of cells as 2; and with strong
staining in > 50% of cells as 3. Statistical analysis indicated that in the
esophageal carcinoma, SPHK1 expression was correlated with depth of tumor
invasion (P < 0.0001) and lymph node metastasis (P = 0.016). There was no
significant association with age, sex or tumor differentiation.
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Page 8 of 15Figure 4 SPHK1 overexpression increased invasive potential of esophageal carcinoma cells. We assessed the impact of gene transfection-
mediated SPHK1 upregulation in EC9706 cells. (A) The two stable expression clones SPHK1-C17 and SPHK1-C24 both had markedly upregulated
SPHK1 expression in EC970 cells. (B) In the transwell invasion assay, SPHK1 overexpression significantly increased the invasion of EC9706 cells. The
numbers of invaded cells in the SPHK1 overexpressing cells (SPHK1-C17 group = 162.0 ± 16.52; SPHK1-C24 group = 173.0 ± 14.73) were higher
compared with that of the vector group (37.33 ± 15.57), EC-9706 group (36.33 ± 4.933) and SPHK1-C7 group (31.33 ± 3.786); ANOVA P < 0.0001.
(C) In 3D Matrigel culture assays, SPHK1 overexpression significantly increased the diameter and the invasive morphology of EC9706 cell clones.
(D, F) SPHK1 overexpression significantly increased the proliferation of EC9706 cells. The OD450 values of the SPHK1-C17 group (3.664 ± 0.792)
and SPHK1-C24 group (3.987 ± 0.632) were higher than that of the vector group (1.432 ± 0.453) and EC-9706 group (2.132 ± 0.334), ANOVA P <
0.031. (E, F) Annexin V assay showed overexpression of the SPHK1 gene did not influence the apoptosis level of EC9706 cells. The percentages of
apoptotic cells in the SPHK1-C17 group (10.2 ± 0.2) and SPHK1-C24 group (7.3 ± 0.5) were comparable to that of the vector group (9.4 ± 3.2)
and EC9706 group (7.3 ± 4.3), ANOVA P = 0.874.
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Page 9 of 15Figure 5 SPHK1 overexpression increased esophageal carcinoma spontaneous metastasis potential. SPHK1 overexpression increased
EC9706 cell growth and spontaneous metastasis in nude mice. Several stable transfected clones were screened and two of them, (A) SPHK1-C17
and SPHK1-C24 were tested in animal experiments. (B, C) The SPHK1 gene promoted tumor growth and tumor burden in nude mice. SPHK1
significantly promoted growth of EC9706 xenografts (SPHK1-C17: 2.62 ± 1.12 cm
3; SPHK1-C24: 2.78 ± 1.14 cm
3) compared to transfected control
(EC9706: 1.42 ± 0.854 cm
3) or control EC9706 cells (EC9706-Ve: 1.35 ± 0.432 cm
3, ANOVA P < 0.01, B and D). Expression of SPHK1 increased
weight of tumors (SPHK1-C17: 2.42 ± 0.654 g; SPHK1-C24: 1.82 ± 0.542 g) compared to transfected control (EC9706: 1.12 ± 0.454 g) or control
EC9706 cells (EC9706-Ve: 1.03 ± 0.434 g, ANOVA P < 0.01, C and D). We also observed that SPHK1 upregulation dramatically increased
spontaneous lung metastasis of EC9706 cells (SPHK1-C17:7.42 ± 3.43 cm
3; SPHK1-C24: 4.21 ± 1.34 cm
3) compared to transfected control (EC9706:
1.34 ± 0.65 cm
3) or control EC9706 cells (EC9706-Ve: 0.63 ± 0.064 cm
3, ANOVA P < 0.05, A and D).
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Page 10 of 15and KYSE2 cells (Figure 6A, B). From the microarray
analysis, we clustered the genes upregulated in the
SPHK1 overexpression clones compared with control
cells (Figure 6C). Expression of SPHK1 was significantly
correlated with that of genes such as IL6, ITGA2, IL8,
EREG, MMP1, ITGA5, MMP3 and AREG.M o s to ft h e s e
genes are the downstream genes of the EGFR pathway,
and most of them such as EREG [33,34], MMP1 [35] and
Figure 6 SPHK1 promoted metastasis via activation of the EGFR pathway. To glean mechanistic insight into the role of SPHK1 in invasion
and metastasis, we surveyed potential links between SPHK1 and key molecules of known relevance to invasion. (A) Western blotting indicated
that the expression of SPHK1 was significantly correlated with the phosphorylation of EGFR. (B) Correspondingly, SPHK1 RNAi decreased the
phosphorylation of EGFR in EC9706-P4 and KYSE2 cells. (C) We clustered the upregulated genes in the SPHK1 overexpression clones compared
with control cells. Expression of SPHK1 was significantly correlated with the expressions of IL6, ITGA2, IL8, EREG, MMP1, ITGA5, MMP3 and AREG.
Most of the genes are the downstream genes of EGFR pathway, and most of them have been associated with the invasion of cancer cells. (D)
Western blotting indicated that the ligands of EGFR (EGF, EREG, and AREG) induced the expression of SPHK1 protein.
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Page 11 of 15AREG [33,34] have been reported to be associated with
the invasion of cancer cells. Western blotting indicated
that the ligands of EGFR, EGF, EREG and AREGinduced
the expression of the SPHK1 protein (Figure 6D).
Discussion
Metastasis is a multi-factorial process, including tumor
cells capable of escaping their normal microenvironment,
traversing into and out of lymphatic or blood vessels and
proliferating in new ‘’soil’’ [36]. Implicit in these stages,
invasion is the critical ability for tumor cells to metastasize
[36]. During invasion, malignant cells reside on or within
two major types of extracellular matrices, the basement
membrane and the stromal matrix [37]. The basement
membrane is one of the most important barriers against
cancer cell invasion [37]. Therefore, for this study, we
used Matrigel, a solubilized basement membrane prepara-
tion from the Engelbreth-Holm-Swarm (EHS) mouse sar-
coma, as a model basement matrix to mimic esophageal
carcinoma invasion in vivo. Although EC9706, an esopha-
geal squamous carcinoma cell line, can invade and form
spontaneous lung metastasis nodules in nu/nu mice, its
metastatic potential is relatively low [38]. The metastatic
ability of EC9706 may arise from a few subclones with
high metastatic potential among the parental cells. By
screening with our in vitro model, the subline EC9706-P4
with high invasion potential was established. This subline
also exhibited high spontaneous metastatic potential in
vivo. Microarray analysis was used to determine which
genes may be involved in invasion and metastasis. How-
ever, the microarray analysis of esophageal cancer tissues
demonstrated that SPHK1 was significantly overexpressed
in these tumor tissues, and that this expression signifi-
cantly correlated with tumor invasion, lymph node metas-
tasis and clinical stage, indicating that SPHK1 is involved
in esophageal carcinoma invasion and metastasis. SPHK1
is up-regulated in many types of cancers and has been sug-
gested as a potentially new therapeutic target. However, it
is not yet known what signals the cancer cells use to
apparently constitutively up-regulate expression of this
enzyme, nor is it clear why it has such a profound role in
tumorigenesis. A recent study examined the role of
SPHK1 in intestinal tumorigenesis in the Min mouse in
which intestinal adenomas develop spontaneously [39].
Deletion of the SPHK1 gene in these mice resulted in
reduction of adenoma size. Concomitantly, epithelial cell
proliferation in the polyps was attenuated, suggesting that
SPHK1 regulates adenoma progression [39].
Exogenous expression of SPHK1 in vitro and in vivo
further showed that it is a key factor in esophageal carci-
noma cell invasion. In the transwell invasion assay, upre-
gulation of SPHK1 expression significantly increased the
invasion of EC9706 cells. Furthermore, upregulation of
SPHK1 expression significantly increased the proliferation
of EC9706 cells in vitro as well as increased EC9706 cell
growth and spontaneous metastasis in nude mice. These
studies support the view that SPHK1 expression is vital for
the maintenance of invasive and metastatic potential of
esophageal carcinoma cells. Interestingly, neutralizing S1P,
the product of SPHK1 enzymatic activity, with a specific
monoclonal antibody was remarkably effective in slowing
progression of cancers, such as lung [40], colon [41],
breast [42,43], melanoma [44] and ovarian cancers [21,45]
in murine xenograft and allograft models [46]. A critical
question raised by these observations is how neutralization
of this simple lysophospholipid can have such dramatic
effects on tumor progression.
To glean mechanistic insight into the role of SPHK1 in
invasion and metastasis, we surveyed potential links
between SPHK1 and key molecules related to EGFR.
Western blot analysis indicated that the expression of
SPHK1 was significantly correlated with the phosphoryla-
tion of EGFR. In clustering the upregulated genes in the
SPHK1 overexpression clones compared with control
cells, SPHK1 expression was significantly correlated with
that of IL6, ITGA2, IL8, EREG, MMP1, ITGA5, MMP3
and AREG. Western blotting indicated that the ligands of
EGFR, EGF, EREG and AREG induced the expression of
SPHK1 protein. These findings provide evidence for cross-
talk between SPHK1 and the EGFR pathway and reveal a
key role for SPHK1 in integrating events downstream of
EGF receptors. An intriguing possibility is that many
growth and angiogenic factors such as EGF and AREG
involved in tumorigenesis may act through SPHK1 activa-
tion [47]. Because both EGF and AREG have been impli-
cated in progression of esophageal cancer, it was of
interest to examine the involvement of SPHK1. There are
numerous reports of rapid and transient activation of
SPHK1 by growth and angiogenic factors [48,49]) that sti-
mulate its phosphorylation at Ser225 [50] and subsequent
translocation to the plasma membrane [51] where its sub-
strate sphingosine resides, resulting in local formation of
S1P [52]. Some cross-talk models between EGFR and
SPHK1/S1P have been proposed previously, Estrada-
Bernal, A et al[53] have reported that treatment of glioma
cell lines with EGF led to increased expression and activity
of SphK1. Expression of EGFRvIII in glioma cells also acti-
vated and induced SphK1. In addition, siRNA to SphK1
partially inhibited EGFRvIII-induced growth and survival
o fg l i o m ac e l l sa sw e l la sE R KM A Pk i n a s ea c t i v a t i o n .
SphK1 activity is necessary for survival of GBM-derived
neurosphere cells, and EGFRvIII partially utilizes SphK1 to
further enhance cell proliferation. Shida, D. et al [54]
reported that LPA markedly enhanced SphK1 mRNA and
protein in gastric cancer MKN1 cells, DLD1 colon cancer
cells and MDA-MB-231 breast cancer cells. LPA transacti-
vated the epidermal growth factor receptor (EGFR) in
these cells, and the EGFR inhibitor AG1478 attenuated
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Page 12 of 15the increased SphK1 and S1P(3) expression induced by
LPA. Their research finally showed that SphK1 is a con-
vergence point of multiple cell surface receptors for three
different ligands, LPA, EGF, and S1P, which have all been
implicated in regulation of motility and invasiveness of
cancer cells. In breast cancer, Sukocheva, O et al [55]
demonstrated that E2-induced EGFR transactivation in
human breast cancer cells is driven via a novel signaling
system controlled by the lipid kinase sphingosine kinase-1
(SphK1). E2 stimulates SphK1 activation and the release of
sphingosine 1-phosphate (S1P), by which E2 is capable of
activating the S1P receptor Edg-3, resulting in the EGFR
transactivation in a matrix metalloprotease-dependent
manner. These findings reveal a key role for SphK1 in the
coupling of the signals between three membrane-spanning
events induced by E2, S1P, and EGF. However, it is still
difficult to understand how such short-lived activation can
be responsible for the profound involvement of SPHK1 in
tumorigenicity or how this relates to its up-regulation in
cancer. Our results imply that SPHK1 may be the central
controller of amplification loops of EGF, AREG and
EREG-EGFR interactions that can contribute to cancer
progression.
Conclusions
We have established an esophageal carcinoma invasion
model and generated a highly invasive tumor cell subline
in which SPHK1 was overexpressed. Further investigation
revealed SPHK1 was significantly correlated with esopha-
geal cancer invasion and metastasis and may be a valu-
able prognostic marker. Our studies have demonstrated
that SPHK1 is involved in upregulation of EREG and
AREG through enhancing EGFR phosphorylation to pro-
mote invasion. Thus, modulating SPHK1 expression or
activity is an attractive additional therapeutic strategy for
treatment of esophageal cancer and perhaps other can-
cers as well. Implementation of pre-clinical and clinical
evaluation of SPHK1 as a novel molecular target for can-
cer therapy is warranted.
Additional material
Additional file 1: The gene expression profiles of EC9706 and
EC9706-P4 were analyzed by microarrays. Between these cell lines,
124 genes were differentially expressed, including 71 upregulated genes
and 53 downregulated genes in EC9706-P4 relative to EC9706 (cutoff,
fold ≥ 2.0).
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